TIA funding allows QEDDI to open to external drug discoveries
TIA is set to boost our capabilities and resources following the announcement of NCRIS 2023 funding by The Hon Jason Clare MP, Minister for Education, and The
Menu
TIA invests in research infrastructure to enable seamless access to expertise and services vital to translate research discoveries into human health impacts. We develop strategic partnerships that are informed by a strong focus on future needs, while working to build a quality workforce – all in support of a vibrant and productive Australian Research and Development ecosystem.
The TIA consortium is enabled by the National Collaborative Research Infrastructure Strategy
TIA enables open and subsidised access to a broad range of expertise across various therapeutic types (see left). Each area is supported by a dedicated broker/facilitator with relevant know-how and experience in areas such as research, clinical trials, translation and manufacturing. These facilitators ensure a smooth process of directing projects to the correct facility, advising and mentoring researchers, and supporting collaboration within and between capabilities.
To browse our accessible capabilities, click the link below.
invested in facilities since 2018
accessible facilities in universities hospitals and research institutes
therapeutic development projects in progress
cleanrooms for manufacturing
expert scientists and
technicians supported
access vouchers awarded totalling $4.8M
TIA is set to boost our capabilities and resources following the announcement of NCRIS 2023 funding by The Hon Jason Clare MP, Minister for Education, and The
Momelotinib, a drug discovered by Australian researchers over several decades, has recently been approved by the US Food and Drug Administration (FDA) for the treatment
Chlamydia is infecting up to half of the koalas living in Queensland and New South Wales, causing blindness and infertility. Antibiotics exist, but they can
We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to their Elders past, present and emerging.
© 2023 Therapeutic Innovation Australia Ltd. Design by Juno Creative.
Discovery and devlopment of advanced biotherapeutics
The National Biologics Facility (NBF) supports therapeutic discovery, from screening of antibody libraries and production of recombinant proteins as small-molecule drug targets, through to novel, engineered biologics, vaccine antigens and diagnostic reagents, from discovery through to the scale-up and manufacturing of clinically-relevant material.
Facilities:
* Accessible via TIA Voucher
Integrated drug discovery and development pipeline
Small Molecule Therapeutics is a long-established pipeline of complementary capabilities supporting translation of projects from hit and lead identification to preclinical efficacy testing. We offer access to compound libraries, high-throughput screening technologies and specialist development and preclinical expertise.
Facilities:
* Screening facilities accessible via TIA voucher
Development and testing of advanced therapeutic medicinal products
TIA brings together key national cell and gene therapy development and manufacturing facilities to enable development of cutting-edge advanced therapies. Our consortium has broad and deep expertise to support your project regardless of your project’s stage of development.
Facilities:
* Accessible via TIA vouchers
Integrated drug discovery and development pipeline
Our RNA Products Capability enables end-to-end mRNA vaccine and therapeutics development within Australia, providing a vibrant and productive pipeline built by onshore researchers – and complementing emerging commercial RNA service providers. We enable access to extensive experience in the design and production of high quality mRNA and synthetic RNA (e.g. siRNA, aptamers and guide RNA) with modified nucleotides, 5-cap and lipid nanoparticles (LNP) formulation for in vitro and in vivo studies.
Facilities:
